博騰股份(300363.SZ)：蘇州博騰擬引入外部投資者先進製造二期基金、高瓴辰鈞等等
格隆匯 4 月 18日丨博騰股份(300363.SZ)公佈，為促進公司基因細胞治療CDMO業務發展，滿足二級控股子公司蘇州博騰生物製藥有限公司(“蘇州博騰”、“目標公司”)後續資本性支出及運營支出的資金需求，公司、公司全資子公司重慶博騰生物醫學研究院有限公司(“博騰生物研究院”)、蘇州博騰擬與先進製造產業投資基金二期(有限合夥)(“先進製造二期基金”)、上海高瓴辰鈞股權投資合夥企業(有限合夥)(“高瓴辰鈞”)、惠每健康(天津)股權投資基金合夥企業(有限合夥)(“惠每健康”)、南京瑞聯管理諮詢合夥企業(有限合夥)(“南京瑞聯”)、蘇州時節啟揚企業管理中心(有限合夥)(“蘇州時節啟揚”)以及重慶博信生物科技合夥企業(有限合夥)(“博信生物”，員工持股平台)共同簽署《投資協議》、《股東協議》。
先進製造二期基金、高瓴辰鈞、惠每健康、南京瑞聯、蘇州時節啟揚以下合稱“投資方”，博騰生物研究院、博信生物以下合稱“現有股東”。
此次增資分為兩個階段：第一階段為投資方擬以3.1億元認購蘇州博騰11421.052632萬元的新增註冊資本，剩餘資金19578.947368萬元作為溢價進入蘇州博騰的資本公積金。同時，公司擬對現有股東博騰生物研究院增資8000萬元，用於其按照投資協議的約定認購蘇州博騰2947.368421萬元的新增註冊資本，剩餘資金5052.631579萬元作為溢價進入蘇州博騰的資本公積金。
第二階段為博騰生物研究院指定第三方(“指定第三方”)擬按照協議約定以1000萬元認購蘇州博騰368.421053萬元的新增註冊資本，剩餘資金631.578947萬元作為溢價進入蘇州博騰的資本公積金。
現有股東博信生物放棄此次優先認購權，並承諾同意按照投資協議的約定接受投資方及現有股東博騰生物研究院的此次增資。
二個階段增資完成後，蘇州博騰的股權結構如下：
此次蘇州博騰通過增資擴股方式引入外部投資者，符合其未來發展戰略。此次增資有利於增強其資金實力，滿足其後續資本性支出及運營支出的資金需求，提升其整體競爭力，促進公司基因細胞治療CDMO業務的發展。此次交易不會影響公司合併報表範圍，交易完成後，博騰生物研究院仍是蘇州博騰的控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
